A female patient in her early 30s was treated with imatinib and high-dose methotrexate (HD-MTX) for Philadelphia chromosome-positive acute lymphoblastic leukaemia. The patient developed delayed MTX clearance and grade 3 acute kidney injury characterised by elevated creatinine (114% increase from baseline). After intensified calcium folinate rescue therapy and hydration, the MTX serum level was appropriately decreased 72 hours after the start of MTX infusion, and renal function returned to normal. Medication analysis by a clinical pharmacist suggested that the concomitant treatment with imatinib likely contributed to the delayed MTX clearance and caused the acute kidney injury.
Keywords: Acute Kidney Injury; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; Drug Monitoring; Leukemia; PHARMACY SERVICE, HOSPITAL; Safety.
© European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.